NUVL Stock Overview
A clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nuvalent, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$82.06 |
| 52 Week High | US$113.51 |
| 52 Week Low | US$61.80 |
| Beta | 1.31 |
| 1 Month Change | -14.79% |
| 3 Month Change | -17.19% |
| 1 Year Change | 9.31% |
| 3 Year Change | 327.17% |
| 5 Year Change | n/a |
| Change since IPO | 337.65% |
Recent News & Updates
Nuvalent: Steps Toward That Favorable Entry Point
Dec 07We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Nov 18
Recent updates
Nuvalent: Steps Toward That Favorable Entry Point
Dec 07We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Nov 18Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Sep 23Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation
Sep 17Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business
Aug 05Nuvalent: Making Precise Progress In Its Oncology Pipeline
Jun 24Nuvalent: NVL-655 Could Bring Blockbuster Potential
Jun 14Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Apr 22Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024
Feb 26Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?
Jan 07Nuvalent GAAP EPS of -$0.38 beats by $0.03
Aug 10Shareholder Returns
| NUVL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.0% | 2.1% | 2.8% |
| 1Y | 9.3% | -3.8% | 24.5% |
Return vs Industry: NUVL exceeded the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: NUVL underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| NUVL volatility | |
|---|---|
| NUVL Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NUVL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NUVL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 127 | Jim Porter | www.nuvalent.com |
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Nuvalent, Inc. Fundamentals Summary
| NUVL fundamental statistics | |
|---|---|
| Market cap | US$5.87b |
| Earnings (TTM) | -US$224.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-26.0x
P/E RatioIs NUVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUVL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$224.29m |
| Earnings | -US$224.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NUVL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:59 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvalent, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Peter Lawson | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |